Immunotherapy Advances Transform Small Cell Lung Cancer Care

Immunotherapy is changing treatment strategies for both limited- and extensive-stage small cell lung cancer, explained Dr. Jacob A. Sands in an interview with CURE. For limited-stage disease, patients now receive immunotherapy after chemotherapy and radiation, with the goal of cure. Sands noted that this approach is well tolerated and improves time to recurrence, with signs it may lead to more patients being cured. In extensive-stage disease, immunotherapy has been standard for several years, but new developments are bringing further progress. Antibody-drug conjugates are showing promise in later lines of therapy, while Imdelltra (tarlatamab) — which links tumor and immune cells — is now an established second-line option, with some patients experiencing long-term disease control. “These are just a handful of the advances happening in small cell lung cancer,” Sands said. Sands is a physician at Dana-Farber Cancer Institute, associate chief of the Lowe Center for Thoracic Oncology, oncology medical director of the International Patient Center, and assistant professor at Harvard Medical School. View more at http://curetoday.com/ Or visit our socials!   / cure_today     / curetoday     / curemagazine     / cure-media-group     / cure_today